THE TREATMENT FOR RECURRENT FEMALE BREAST CANCER AFTER INITIAL ENDOCRINE THERAPY AMONG TAIWANESE POPULATION
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- clinical use of aromatase inhibitors in breast cancer
研究概览
简要总结
Breast cancer is the most common cancer in Taiwanese women. Most of them were diagnosed in relatively early stages. Only 700 metastatic breast cancer were registered in Official Cancer Registration 2012, while more than11,305 were registered as early breast cancer. With broadly application of aromatase inhibitors, hormonal-receptor-positive breast cancer patients can survive longer and longer. However, there is no prevalence of metastatic breast cancer can be available yet. NHIA database coverage is more than 90% population in Taiwan, thus it can be an appropriate surrogate of prevalence. In this retrospective database analysis, we will explore the real world experience on aromatase inhibitor use for breast cancer in Taiwan.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •hormonal receptor positive, human epidermal growth factor receptor 2 negative breast cancer
排除标准
- 未提供
结局指标
主要结局
clinical use of aromatase inhibitors in breast cancer
时间窗: base line, up to 60 months
duration of treatment
次要结局
- overall survival(base line, up to 60 months)
- treatment cost(base line, up to 60 months)
- prevalence(base line up to 60 months)
- dose exposure(base line, up to 60 months)